A Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the clinical outcome at 30 days follow-up after administration of a single subcutaneous injection of zalunfiban versus placebo in STEMI subjects in the pre-hospital setting.
This multi-center study designed to enroll 2499 subjects will be conducted at up to 45 clinical sites (hospitals/ambulance services) in the Netherlands, Czech Republic, Hungary, France, Canada and the US.
